Your browser is no longer supported. Please, upgrade your browser.
GTHX G1 Therapeutics, Inc. daily Stock Chart
GTHX [NASD]
G1 Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.46 Insider Own10.65% Shs Outstand37.79M Perf Week-6.64%
Market Cap486.65M Forward P/E- EPS next Y-3.84 Insider Trans0.02% Shs Float33.99M Perf Month2.76%
Income-130.00M PEG- EPS next Q-0.31 Inst Own90.00% Short Float20.16% Perf Quarter-29.63%
Sales2.10M P/S231.74 EPS this Y-27.60% Inst Trans-3.66% Short Ratio9.47 Perf Half Y-10.91%
Book/sh5.39 P/B2.35 EPS next Y-38.50% ROA-46.80% Target Price- Perf Year-41.98%
Cash/sh6.10 P/C2.08 EPS next 5Y- ROE-53.40% 52W Range8.80 - 31.38 Perf YTD-52.10%
Dividend- P/FCF- EPS past 5Y-65.60% ROI- 52W High-59.66% Beta2.06
Dividend %- Quick Ratio11.00 Sales past 5Y- Gross Margin- 52W Low43.86% ATR0.68
Employees104 Current Ratio11.00 Sales Q/Q- Oper. Margin- RSI (14)43.80 Volatility5.22% 5.12%
OptionableYes Debt/Eq0.10 EPS Q/Q-0.80% Profit Margin- Rel Volume0.42 Prev Close12.80
ShortableYes LT Debt/Eq0.10 EarningsAug 05 AMC Payout- Avg Volume723.70K Price12.66
Recom1.60 SMA200.50% SMA50-11.26% SMA200-23.98% Volume303,468 Change-1.09%
Jun-26-20Initiated ROTH Capital Buy $55
Jan-21-20Reiterated H.C. Wainwright Buy $72 → $82
Aug-08-19Upgrade JP Morgan Neutral → Overweight
Feb-07-19Initiated B. Riley FBR Buy $55
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-20-18Initiated Raymond James Strong Buy
Nov-08-18Reiterated Needham Buy $76 → $74
Sep-10-18Resumed BTIG Research Buy $80
May-29-18Initiated H.C. Wainwright Buy $61
May-18-18Reiterated Needham Buy $42 → $60
Oct-15-20 07:00AM  
Sep-30-20 04:01PM  
Sep-14-20 07:00AM  
Sep-02-20 07:01AM  
Aug-17-20 06:00AM  
Aug-05-20 04:01PM  
Aug-04-20 07:00AM  
Aug-03-20 07:00AM  
Jul-29-20 07:01AM  
Jul-23-20 08:25AM  
Jul-22-20 06:00PM  
Jun-30-20 04:36PM  
04:10PM  
Jun-22-20 06:00AM  
Jun-18-20 12:27PM  
Jun-16-20 07:09AM  
Jun-11-20 08:36AM  
Jun-01-20 04:01PM  
May-13-20 05:31PM  
May-07-20 10:30AM  
May-06-20 04:01PM  
07:36AM  
Apr-29-20 07:00AM  
Apr-07-20 07:00AM  
Mar-13-20 07:12AM  
Mar-12-20 08:05AM  
Feb-26-20 04:01PM  
Feb-24-20 02:59PM  
07:00AM  
Feb-19-20 07:00AM  
Feb-18-20 07:00AM  
Feb-17-20 07:00AM  
Feb-06-20 07:00AM  
Jan-14-20 09:01AM  
07:00AM  
Jan-07-20 07:00AM  
Dec-11-19 06:00PM  
Nov-26-19 07:00AM  
Nov-21-19 09:44AM  
Nov-12-19 07:00AM  
Nov-08-19 08:49AM  
Nov-07-19 06:07AM  
Nov-05-19 04:00PM  
Oct-29-19 07:00AM  
Oct-27-19 08:14PM  
Sep-30-19 01:13PM  
Sep-29-19 06:00AM  
Sep-28-19 04:15AM  
Sep-10-19 06:01AM  
Sep-03-19 07:00AM  
Aug-28-19 07:27AM  
Aug-08-19 12:42AM  
Aug-07-19 04:01PM  
Aug-06-19 07:00AM  
Jul-31-19 07:00AM  
Jul-30-19 07:01AM  
Jul-18-19 08:22AM  
Jun-28-19 07:56PM  
Jun-23-19 09:00AM  
Jun-19-19 01:58PM  
12:30PM  
09:48AM  
Jun-18-19 04:33PM  
03:14PM  
06:00AM  
Jun-14-19 07:01AM  
Jun-13-19 07:01AM  
Jun-11-19 07:00AM  
Jun-01-19 04:00PM  
May-19-19 09:29PM  
May-16-19 07:00AM  
May-13-19 01:12PM  
07:00AM  
May-12-19 09:04AM  
May-09-19 04:01PM  
May-05-19 08:15PM  
May-02-19 07:00AM  
May-01-19 02:15PM  
Apr-30-19 03:21PM  
02:28PM  
08:06AM  
Apr-29-19 05:07PM  
04:01PM  
Apr-02-19 07:00AM  
Mar-05-19 06:08AM  
Mar-04-19 07:00AM  
Feb-28-19 06:38PM  
04:01PM  
Feb-27-19 07:00AM  
Feb-21-19 07:00AM  
Feb-20-19 05:24PM  
Feb-11-19 06:41AM  
Jan-23-19 08:11AM  
Jan-07-19 08:44AM  
Jan-03-19 02:48PM  
Dec-27-18 09:23AM  
07:00AM  
Dec-21-18 11:00AM  
Dec-20-18 05:27PM  
10:28AM  
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hanson James S.General CounselSep 04Buy14.951,00014,9504,000Sep 08 08:38 PM
Malik RajeshCh. Medical Officer & SVP R&DMar 13Option Exercise0.392,50097529,200Mar 16 07:00 AM
Moses Jennifer K.CFOMar 13Option Exercise3.722,0007,44011,000Mar 16 07:00 AM
Velleca Mark A.President and CEOMar 13Option Exercise0.393,0001,17037,000Mar 16 07:00 AM
Moses Jennifer K.CFOJan 23Option Exercise3.721,0003,7209,000Jan 24 04:58 PM
Velleca Mark A.President and CEOJan 23Option Exercise0.396,0002,34034,000Jan 24 04:59 PM
Malik RajeshCh. Medical Officer & SVP R&DJan 23Option Exercise0.395,0001,95026,700Jan 24 04:58 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.